Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Pricing & Reimbursement
|
Regulation
|
Healthcare Policy
|
Pharmacovigilance
|
Intellectual Property
|
Policy & Regulation - Pricing & Reimbursement
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
China spending big as health reforms gather pace
17 March 2010
China's central government spent Yuan116.2 billion ($17.1 billion) on measures to support reforms to the national pharmaceutical and healthcare system in 2009, and is gearing up for further changes this year, including the full adoption of new ...
Key MEP says EU patient information proposal "must go through"
17 March 2010
The MEP responsible for guiding the controversial patient information proposal through the European Parliament says he is not prepared to see it derailed by opposition from member state ministers and certain political groupings in parliament. ...
FDA approves Watson's new formulation of Trelstar for prostate cancer
16 March 2010
The US FDA has approved Watson Pharmaceutical 's six-month formulation of Trelstar, Trelstar 22.5 mg (triptorelin pamoate for injectable suspension), for the treatment of advanced prostate cancer. Launch is expected in May. The six-month formulation ...
Emerging markets to make up 48% of pharma growth, IMS Health says
16 March 2010
IMS Health is predicting that emerging markets will expand by $90 billion during 2009-13, contributing 48% of annual pharmaceutical market growth in 2013, a jump from 37% in 2009. This comes at time when many multinational pharma firms are looking ...
Plavix gets US "boxed warning" about poor metabolisers
15 March 2010
Bristol-Myers Squibb and Sanofi-Aventis have added a "boxed warning" to the US label for the blockbuster blood thinner Plavix (clopidogrel), in order to warn about the diminished effectiveness of the drug in patients with a certain variant of the ...
 
Market Insight: Big pharma hit by Greece's fiscal crisis
09 March 2010
Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of the challenges facing the sector in Greece, Elizabeth Sukkar, Scrip's world editor, discovers. ...
Market Insight - Pharma sector in Turkey to shrink 25% under tough conditions
02 March 2010
The pharmaceutical industry has long eyed Turkey as one of its key emerging markets, but recent government action, which could see medicine access delayed by years, is giving it a wake-up call, ...
Market Insight - Power of observation propels comparative effectiveness research into the mainstream
02 March 2010
US agencies are making inroads in the use of comparative effectiveness research to support more robust decision-making. Observational studies are an emerging force in this area and promise to ...
 
Face to Face with Sandoz's "growth guy" Jeff George
04 March 2010
Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big push in emerging markets, a leadership position in biosimilars and an expanded focus on injectables, he ...
Interview: European Medicines Agency gets serious about its global strategy
29 January 2010
Developing relationships with medicine regulators in China and India is just one of the challenges facing Emer Cooke, the international face of the European Medicines Agency (EMA), Scrip's Elizabeth ...
Face to face: Ex-Novartis manager takes two-step approach to women's health at Lumavita
12 January 2010
Many pharmaceutical and biotech companies devote themselves to the discovery and development of novel drugs for unmet medical needs. However, with R&D costs and regulatory hurdles multiplying, and ...
 
Pfizer's fine: a revisit of self-regulation
10 September 2009
The US is a great place to do business. Being an almost free market, the profits are good, but so also are the temptations. So if you can't be bothered to put the money into a clinical trial to find a new indication for your product, you could ...
Commentary: 10 pro-innovation biopartnering trends
01 September 2009
1. risk aversion converges with focus on quality The rise and rise of the biotech sector and big pharma's increasing reliance on biological products as sources of future innovation are well established industry trends. Interesting, therefore, to ...
US agencies move forward with comparative effectiveness research plans
20 August 2009
As the US Congress debates the shape of a permanent comparative effectiveness research (CER) programme and who should run it, the agencies that received $1.1 billion in CER funding under an economic stimulus bill earlier this year have started ...
 
Decision models for assessing the cost effectiveness of drug-eluting stents
01 June 2005
Percutaneous coronary intervention is an increasingly common treatment for many people with coronary disease. Randomised trials using antiproliferative, drug-eluting stents (DES) have shown important reductions in the need for repeat procedures ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm